Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis

clipboard-pencil

About the study

This is a multi-center, open-label extension (OLE) study in patients with plaque psoriasis who have completed their participation in a previous plaque psoriasis study of ESK-001.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:


  1. Must have completed a prior ESK-001 study
  2. Men and Women must use highly effective methods of contraception for the entirety of the study

EXCLUSION CRITERIA

Exclusion Criteria:


  1. Pregnancy
  2. Received a prohibited concomitant medication

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition
Plaque Psoriasis
Age (in years)
18+
Phase
PHASE2
Participants needed
165
Est. Completion Date
Dec 30, 2026
Treatment type
INTERVENTIONAL

Sponsor
Alumis Inc
ClinicalTrials.gov identifier
NCT05739435
Study number
ESK-001-007

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?